TNF and interstitial lung disease: Regarding the duration of reporting in VigiBase for ILD from the start of dosing, the longest median duration was for adalimumab among TNF‐α inhibitors, with a mean of 644.7 days and a median (interquartile range: 25%–75%) of 320.5 (117.1–821.9) days.